LifeMD’s (LFMD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of LifeMD (NASDAQ:LFMD) in a research note released on Monday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

LFMD has been the topic of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th. B. Riley started coverage on shares of LifeMD in a report on Friday, August 23rd. They set a “buy” rating and a $11.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, LifeMD presently has a consensus rating of “Buy” and an average target price of $12.00.

LifeMD Stock Down 2.4 %

Shares of NASDAQ:LFMD opened at $6.99 on Monday. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83. The stock has a fifty day simple moving average of $4.95 and a two-hundred day simple moving average of $6.46. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88. The stock has a market capitalization of $302.74 million, a price-to-earnings ratio of -10.92 and a beta of 1.23.

Hedge Funds Weigh In On LifeMD

Several hedge funds and other institutional investors have recently bought and sold shares of LFMD. Vanguard Group Inc. lifted its position in LifeMD by 12.5% during the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares during the period. Royce & Associates LP lifted its holdings in shares of LifeMD by 14.6% during the 3rd quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock valued at $4,721,000 after buying an additional 114,710 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of LifeMD by 6.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 765,916 shares of the company’s stock valued at $4,013,000 after buying an additional 48,201 shares during the period. Cubist Systematic Strategies LLC boosted its stake in shares of LifeMD by 15.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 551,344 shares of the company’s stock worth $3,782,000 after buying an additional 72,203 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of LifeMD by 63.6% in the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock worth $1,609,000 after acquiring an additional 91,183 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.